Blanket Purchase Agreement 36F79721D0166-36E79721A0015
Award Date
5/19/21
Last Date to Order
5/18/26
Federal Agency
National Acquisition Center
Awardee
Biocryst Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Blanket Purchase Agreement was awarded as a single award by the Department of Veterans Affairs National Acquisition Center to Biocryst Pharmaceuticals, Inc. for the procurement of RAPIVAB. With a potential value of $625,000, the period of performance under the BPA extends through May 14, 2021. The BPA facilitates the delivery of RAPIVAB to treat influenza. As the leading cause of vaccine-preventable death in the United States, influenza places significant burden each year on the health...
Biocryst Pharmaceuticals Inc., a biotechnology company specializing in rare disease treatments, holds a multiple-award Federal Supply Schedule (FSS) contract (36F79721D0166) with a $1.25 million ceiling under GSA Schedule 61-IB for Pharmaceuticals and Drugs. This IDV serves as the parent vehicle for numerous delivery orders from the U.S. Department of Veterans Affairs (VA) to supply Biocryst's pharmaceutical products, such as ORLADEYO for hereditary angioedema and RAPIVAB for influenza...
This federal contract Indefinite Delivery Vehicle (IDV) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Biocryst Pharmaceuticals Inc., a for-profit pharmaceutical company based in Durham, North Carolina. The single-award IDV, valued at $90,000,000.00, is for the delivery of drugs and biologicals, with an ultimate completion date of November 2, 2011. The award includes a $22,500,000.00 Firm Fixed Price Delivery Order task order...
The federal contract IDV award is a Blanket Purchase Agreement (BPA) established by the National Acquisition Center, a civilian agency, with Horizon Therapeutics USA, Inc., a for-profit biotechnology company. The single-award BPA has a ceiling value of $31,375,000 and a performance period from September 2024 to September 2025. It is set up against the GSA Schedule for Pharmaceuticals and Drugs (FSS-61-IB) and allows VA medical centers and Veterans Integrated Service Networks (VISNs) to...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the U.S. Department of Veterans Affairs National Acquisition Center to Rare Disease Therapeutics, Inc., a woman-owned small business. The BPA, valued at $250,000, is based on the company's GSA Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) and has an ultimate completion date of May 31, 2026. This single-award BPA allows the VA to access Rare Disease Therapeutics' catalog of specialty pharmaceutical products,...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Grifols USA LLC, a for-profit manufacturer of pharmaceutical goods. The $107.5 million BPA is for the provision of PROLASTIN-C, an alpha1-proteinase inhibitor used to treat alpha1-antitrypsin deficiency. This IDV contract allows federal agencies, particularly the VA, Department of Justice's Bureau of Prisons, and Centers...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a civilian agency under the Department of Veterans Affairs (VA), to Biogen U.S. Corporation. The BPA is valued at $430,578.10 and has a period of performance through December 3, 2025. It was placed against Biogen's Pharmaceuticals and Drugs (FSS-61-IB) General Services Administration (GSA) Schedule contract, indicating the company's expertise in providing specialized pharmaceutical products...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a component of the Department of Veterans Affairs (VA), to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The BPA, valued at $83.5 million, is for a one-year period from May 2024 to May 2025. The BPA covers the procurement of specialized medications used to treat pulmonary arterial hypertension, including Tracleer, Zavesca, Ventavis, Veletri, Opsumit, Uptravi, and...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs National Acquisition Center to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $3.1 million single-award contract establishes an Indefinite Delivery Vehicle (IDV) for the procurement of orexin inhibitors, a class of sleep-regulating medications, over a one-year base period with four option years. This BPA aims to ensure the availability of...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Adma Biologics, Inc., a for-profit organization. The BPA has a total ceiling value of $49,000,000 and a period of performance running through July 31, 2025. The primary purpose of this BPA is to provide the federal government, particularly agencies within the Veterans Health Administration, with access to Adma Biologics' specialized pharmaceutical products, specifically ASCENIV and...